← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd))

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
CGTAAVBiologicstaleNovartis PharmaceuticalsPhase 2

Rapcabtagene autoleucel (Rapcabtagene autoleucel)

ANCA Associated Vasculitis (AAV) · ANCA Associated Vasculitis (AAV)

#ANCAAssociatedVasculitisAAV#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 9상태 RECRUITING
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 2

TCR-like CAR-T (TCR-like CAR-T)

Safety and Efficacy of TCR-like CAR-T · Safety and Efficacy of TCR-like CAR-T

#SafetyandEfficacyofTCR-likeCAR-T#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 9상태 RECRUITING
CGTBiologicstaleKitePhase 2

Tecartus (Tecartus)

Acute Lymphoblastic Leukemia; Large B-cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 86%임상시험 9상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

XmAb20717 (XmAb20717)

Biliary Tract Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 9상태 RECRUITING
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab Vedotin, Rituximab (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab vedotin and Rituximab (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleCelldex TherapeuticsPreclinical

glembatumumab vedotin (glembatumumab vedotin)

Metastatic gpNMB Expressing Triple Negative Breast Cancer · Melanoma

#Melanoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 9상태 ACTIVE
AntibodystaleMacroGenicsPhase 1

lorigerlimab (lorigerlimab)

Advanced Solid Tumor; Castration-Resistant Prostatic Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 9상태 ACTIVE
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, 6 cycle RC48 and JS001)

Urology · Urology

#Urology#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 8상태 RECRUITING
ADCBiologicstaleAbbViePhase 2

ABT-414 (ABT-414)

Malignant Glioma; Glioblastoma Multiforme · Malignant Glioma

#MalignantGlioma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 14.3%임상시험 8상태 ACTIVE
CGTBiologicstaleStephan Grupp MD PhDPhase 1

CART123 (Anti-CD123 LV redirected T cells, Anti-CD123 LV redirected T cells (CART123))

Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 8상태 RECRUITING
ADCBiologicstalePfizerPreclinical

Antibody Drug Conjugate Chemotherapeutic (Antibody Drug Conjugate Chemotherapeutic)

CD33 Positive Acute Myelogenous Leukemia · CD33

#CD33#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51%임상시험 8상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Talazoparib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 0%임상시험 8상태 RECRUITING
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 8상태 RECRUITING
ADCBiologicstaleBayerPhase 1

BAY94-9343 (BAY94-9343)

Neoplasms · Oncology

#Oncology#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 7.2%임상시험 8상태 ACTIVE
ADCBiologicstaleMedImmune LLCPhase 1

BL22 immunotoxin (BL22 immunotoxin)

Leukemia; Lymphoma · Leukemia

#Leukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0%임상시험 8상태 ACTIVE
AntibodystaleJin-hong ChenPhase 2

Cadonilimab+regorafenib (Cadonilimab+regorafenib)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 8상태 ACTIVE
ADCBiologicstaleAbbViePhase 3

Depatuxizumab mafodotin (Depatuxizumab mafodotin)

Glioblastoma · Glioblastoma

#Glioblastoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 14.3%임상시험 8상태 ACTIVE
AntibodystaleMacroGenicsPhase 2

Flotetuzumab (Flotetuzumab)

Relapsed Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia

#RelapsedAcuteMyeloidLeukemia#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 8상태 DISCONTINUED

45 / 177 페이지

← 이전다음 →